About Us


A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. 


The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised financing of $136 million (The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.


We are currently advancing a pipeline of programs towards the clinic.

A fully integrated discovery, development and manufacturing organization

An experienced management team supported by a renowned Scientific Advisory Board and a Board of Directors with the diverse skills and experience needed to drive success.

Management team

President & CEO

Founder & CSO


Drug Discovery

Board of Directors

President and Chief Executive Officer, A2 Biotherapeutics

Chief Scientific Officer, A2 Biotherapeutics

President, Innovative Targeting Solutions

Managing Partner, The Column Group

Managing Director, Vida Ventures

Founding Partner, Samsara BioCapital

Partner, Nextech Invest

Chief Operating Officer, Nutcracker Therapeutics

Scientific Advisory Board

Stanford, human immunology & TCRs

Washington U., immunology & neo-antigens

Fred Hutchinson, cancer cell therapy

Harvard, T cell biology

Therapeutic Technology


Vida Logo.png
Casdin Capital Logo - Transparent - High